Oct 20, 2026 - 7 AI models call the biggest movers in the morning session. 4 models finished positive

Asked Oct 20, 10:07 AM EDT (morning session). GPT-6, Muse Spark 1.1, Perplexity, Grok 4.5, Gemini 3 Pro, DeepSeek and Claude Sonnet 5.5 answered the same standard prompt independently. Window: from Oct 20, 10:07 AM EDT to Oct 21, 10:07 AM EDT, the same time one session later. Benchmark: SPY.

Five direction-adjusted close-to-close returns; a down call reverses the sign. The score is the mean signed return, without subtracting the benchmark. In each chart SPY is on the left and the picks on the right, every candle drawn from zero to that asset's move; ✓ marks a pick that moved the way it was called.

Model	Correct	Hit rate	Return	SPY	Directional return
GPT-6	2/5	40.00%	-0.51%	0.13%	-0.51%
Muse Spark 1.1	3/5	60.00%	2.01%	0.13%	2.01%
Perplexity	2/5	40.00%	0.14%	0.13%	0.14%
Grok 4.5	4/5	80.00%	2.30%	0.13%	2.30%
Gemini 3 Pro	2/5	40.00%	-0.37%	0.13%	-0.37%
DeepSeek	1/4	25.00%	-1.17%	0.13%	-1.17%
Claude Sonnet 5.5	3/5	60.00%	0.82%	0.13%	0.82%

GPT-6

View full picks and reasoning

US equities entered October 20 following a narrow technology-led recovery on October 19, when the S&P 500 gained approximately 0.4% and the Nasdaq gained 1.1%, despite negative market breadth. Tuesday's environment is less supportive: elevated oil prices, geopolitical tensions, high Treasury yields, and renewed pressure on technology stocks favor selective reversals and continued weakness in financially vulnerable companies. The five selections comprise three October 19 gainers and two losers. Two are predicted to reverse their previous-session gains, two to continue their previous-session declines, and one to extend a fundamentally supported rally. All five passed the October 19 closing-price, market-capitalization, and 20-day dollar-liquidity thresholds. Average daily dollar volume was calculated from the 20 completed trading sessions ending October 19 as the arithmetic mean of daily closing price multiplied by daily share volume, using split-adjusted historical prices. Market capitalizations are reported at the October 19 close rather than inferred from current intraday prices. Reference prices are the latest independently retrieved October 20 intraday quotes, with individual timestamps disclosed. Intraday prices do not replace October 19 source-session percentage changes. Primary scoring after settlement is the arithmetic mean of signed returns, with long-direction returns positive when the ending price exceeds the starting price and short-direction returns positive when the ending price is lower. Directional accuracy is the fraction of five correct predictions. Neither realized score nor directional accuracy is available before the October 21 evaluation. All assessments use information available during the October 20 research window.

1. ALM down — confidence 67%. Rank 1: Almonty Industries declined 10.17% during the October 19 regular session, making it one of the largest verified declines among sufficiently capitalized and liquid common stocks. The decline extended a persistent downtrend from approximately $13.52 on October 5 to $8.83 on October 19. The bearish thesis is continuation rather than reversal: weakening tungsten-price expectations, an earlier analyst price-target reduction, and concerns about project execution have undermined confidence in the near-term investment case. The October 19 Investor Day did not reverse selling pressure. Catalyst assessment: the company's operating projects and tungsten-price exposure are substantive, while the precise contribution of financing concerns and speculative selling to Monday's decline is not independently established. Tickeron reported tungsten-price uncertainty and profit-taking, while Almonty's official communications confirm its Investor Day and ongoing Sangdong development. The October 20 quote of $8.70 was observed at 09:37 EDT, approximately 16 minutes before the prediction timestamp and about 18 minutes before the research cutoff. This intraday quote is below the October 19 close of $8.83, supporting near-term downside momentum. The 20-session average dollar turnover was approximately $78.87 million, calculated from historical daily closing prices and volumes. Main risks are an oversold rebound, positive production announcements, and renewed strategic-minerals demand. Direction down represents continuation of the negative October 19 return.
   Return: 7.10%; alpha: -7.22%.
2. CLF down — confidence 64%. Rank 2: Cleveland-Cliffs gained 16.34% on October 19, placing it among the largest liquid-stock gainers. Its earnings-related catalyst was substantive: third-quarter revenue reached approximately $5.61 billion, adjusted EBITDA was $612 million, and management forecast more than $4 billion in adjusted EBITDA for 2027, considerably above published analyst expectations. However, the magnitude of the initial reaction creates a near-term profit-taking opportunity. The stock subsequently traded at $13.08 at 09:52 EDT on October 20, approximately seven minutes before the research cutoff, compared with the October 19 close of $14.10. This roughly 7.2% intraday decline suggests that buyers have not sustained Monday's enthusiasm. The predicted direction is down, classified as a reversal of Monday's positive regular-session return, not continuation of Tuesday's opening weakness. Catalyst assessment: earnings results and management guidance are substantive and documented by company reporting and financial-news coverage, including The Wall Street Journal and Barron's. The bearish one-session thesis is based on price exhaustion and profit-taking rather than deterioration in reported results. Risks include renewed buying after the earnings upgrade, steel-tariff support, short covering, and unexpectedly strong institutional demand. The 20-session average dollar turnover was approximately $268.90 million.
   Return: 4.80%; alpha: -4.93%.
3. IBRX down — confidence 62%. Rank 3: ImmunityBio declined 8.28% on October 19, following another 8.20% decline on October 16. This consecutive weakness suggests persistent selling rather than an isolated one-day reaction. The company has experienced substantial operating losses and continuing cash requirements despite growing revenue from its immunotherapy business. Its elevated sales multiple and substantial short interest increase sensitivity to changes in growth expectations. The predicted direction is down, representing continuation of the negative October 19 return. Catalyst assessment: operating losses, cash consumption, historical earnings performance, and valuation concerns are substantive, as discussed in Trefis financial analysis. However, no independently verified company-specific adverse announcement on October 19 was established as the definitive cause of the session's decline. The immediate price catalyst is therefore classified as sentiment-driven rather than confirmed fundamental news. The latest retrieved October 20 quote was $8.34 at 09:46 EDT, approximately 13 minutes before the research cutoff, compared with the previous regular close of $8.42. Twenty-session average dollar turnover was approximately $156.76 million, comfortably exceeding the liquidity requirement. Risks include sharp short covering, favorable ANKTIVA commercialization developments, regulatory announcements, and renewed biotechnology-sector buying.
   Return: -0.23%; alpha: 0.11%.
4. IRON down — confidence 59%. Rank 4: Disc Medicine surged 38.86% during the October 19 regular session, leading the verified liquid gainers. Its Phase 3 APOLLO trial of bitopertin met primary and secondary endpoints in erythropoietic protoporphyria, providing important clinical evidence for a potential FDA resubmission. This is a substantive positive catalyst, supported by company trial disclosures and independent reporting. Nevertheless, after the close on October 19, Disc Medicine announced a proposed $350 million public offering of common stock and pre-funded warrants, with an additional underwriter option. The proposed financing represents a substantive potential supply and dilution overhang following the exceptionally large one-day appreciation. This creates a plausible sell-the-news reversal despite the favorable trial results and subsequent analyst price-target increases. The latest retrieved regular-session quote was $78.49 at 09:54 EDT on October 20, approximately five minutes before the research cutoff, against the October 19 close of $78.93. The stock's small negative opening-session performance supports, but does not establish, the predicted reversal. The 20-session average dollar turnover was approximately $70.95 million. Risks include strong institutional accumulation, an attractively priced offering, continued analyst upgrades, and further revaluation of the drug's commercial potential. Direction down is explicitly a reversal of the positive October 19 move.
   Return: 1.69%; alpha: -1.82%.
5. MANE up — confidence 56%. Rank 5: Veradermics advanced 12.37% during the October 19 regular session following positive topline data from its Phase 3 Study 304 of VDPHL01, an extended-release oral treatment for male pattern hair loss. The 536-participant study met its primary and secondary endpoints with strong statistical significance. Reported increases in target-area hair count exceeded placebo, and the company reported no treatment-related serious adverse events. These results were documented in an October 19 company release and SEC Form 8-K, with independent coverage by Reuters. Catalyst assessment: substantive clinical evidence rather than an unsubstantiated promotional announcement. Although the stock traded at $118.41 at 09:51 EDT on October 20, approximately eight minutes before the research cutoff and below the October 19 close of $122.28, a meaningful clinical de-risking event may support additional institutional buying after initial profit-taking. The forecast is direction up and hypothesis continuation because October 19 was a positive session; Tuesday's weaker opening does not change that classification. The 20-session average dollar turnover was approximately $107.73 million. Risks include expensive expectations already embedded in the valuation, additional regulatory requirements, commercialization costs, broader biotechnology weakness, and sell-the-news activity. Confidence is lower than for the downside selections because the early October 20 price reaction conflicts with the fundamental continuation thesis.
   Return: 10.83%; alpha: 10.70%.

Full prediction and audit record

Muse Spark 1.1

View full picks and reasoning

US market on Oct 20 premarket mixed with earnings driving extremes. Large-cap consumer and industrial names show earnings-driven moves. Expect continuation for strong earnings beats (HAS, KVYO) and further downside pressure for misses and financing overhangs (GM, GE, IREN) into next close, with high-volume names tradable in size.

1. HAS up — confidence 75%. Top premarket gainer +8.31% at $106.67 on earnings release. Substantive catalyst: Hasbro Q3 earnings beat reported Oct 20. Price $5+ and market cap $13.93B passes floors. Average daily traded value $167.99M from Finnhub satisfies $20M floor. Used live quote $103.96 as reference_price (intraday Oct 20). Continuation up expected as earnings momentum persists.
   Return: 8.08%; alpha: 7.95%.
2. GM down — confidence 70%. Top premarket loser -5.66% at $78.06 on earnings release. Substantive catalyst: General Motors Q3 earnings miss/guidance cut driving 2.73M premarket volume 7.8x. Market cap $72.61B from WallStreetZen at $82.75 close, price >$5. Dollar volume >$500M typical passes floor. Used Finnhub current price $78.3817 as latest quote. Continuation down likely as auto earnings weakness extends.
   Return: -2.86%; alpha: 2.73%.
3. GE down — confidence 65%. Premarket loser -4.94% at $295.90 on earnings release. Substantive catalyst: GE Aerospace earnings release showing pressure, Finnhub reports -2.88% 5-day return, market cap $325.62B. Meets $5, $1B, $20M floors easily. Used Finnhub current price $299.33. Continuation down thesis as aerospace earnings disappointment weighs into next session.
   Return: 2.32%; alpha: -2.45%.
4. IREN down — confidence 62%. Premarket loser -6.04% at $26.05 on financing catalyst (public offering). Speculative/substantive mix: dilution overhang outweighs AI infrastructure theme. Market cap $10.91B, current price $25.805, previous close $27.73 per Finnhub. Passes floors. Average dollar volume high due to 68M share volume at $26.99 close ~ $1.8B. Continuation down expected on financing pressure.
   Return: 2.31%; alpha: -2.44%.
5. KVYO up — confidence 60%. Premarket gainer +8.62% at $19.03 on unusual volume. Speculative momentum but with software SaaS base. Market cap $4.86B, current price $19.51, previous close $17.52 per Finnhub. Passes floors. Average dollar volume >$50M given 2.12M vol spike. Continuation up thesis as unusual volume often carries through next session.
   Return: 3.73%; alpha: 3.60%.

Full prediction and audit record

Perplexity

View full picks and reasoning

The source session was Monday, October 20, 2026's prior regular session (October 19), when technology and materials names led gains while several earnings-related and downgraded names declined. I favor selective continuation in liquid AI-hardware and software gainers, but expect mean reversion in the largest speculative single-day spikes, particularly Cleveland-Cliffs and Agios. The fifth selection, Ameriprise, is a continuation-down pick after a broker downgrade; its live quote and capitalization could not be verified before submission, so those fields are omitted rather than estimated.

1. WDC up — confidence 62%. Western Digital rose 6.09% in the source session as chip and AI-hardware stocks rebounded; the catalyst is substantive insofar as it reflects a broad storage/semiconductor recovery, though it is partly thematic rather than company-specific. I expect continuation because the move occurred on near-average volume in a highly liquid mega-cap and the stock remains far below its 52-week high. Reference price is the latest confirmed regular-session close of $352.21 on October 19; no fresher regular-session quote was available before the U.S. open. Risks: renewed AI-capital-spending concerns and a weak opening could reverse the rebound. The 20-day average dollar volume is estimated from the reported 7,833,956-share average volume and the $352.21 close.
   Return: 4.41%; alpha: 4.29%.
2. DDOG up — confidence 58%. Datadog gained 5.36% after a Bernstein upgrade to Outperform citing AI-related token-consumption growth; this is a substantive analyst catalyst, although upgrade-driven moves can fade. I expect continuation because the stock is extremely liquid, trades well above the price floor, and entered the session with positive fundamental sponsorship. Reference price is the latest available intraday quote of $261.21 on October 20. Risks include a high valuation and broader AI-software de-rating. The 20-day average dollar volume is estimated from the reported 2.72 million-share average volume and the $261.21 quote.
   Return: 5.05%; alpha: 4.93%.
3. CLF down — confidence 55%. Cleveland-Cliffs surged 16.34% in the source session, an unusually large move for a steel producer; the available research did not identify a durable company-specific fundamental catalyst, making the advance largely speculative. I expect reversal lower after such an outsized gain, especially with premarket trading indicating a roughly 2% decline. Reference price is the latest available premarket quote of $13.80 on October 20; the market cap and average dollar volume were verified at the October 19 close. Risks: if the rally reflects a material demand, pricing, or policy development not captured in the sources reviewed, continuation could occur. The 20-day average dollar volume is estimated from the reported 18.10 million-share average volume and the $14.13 latest available price.
   Return: 4.80%; alpha: -4.93%.
4. AGIO down — confidence 54%. Agios Pharmaceuticals jumped 11.43% in the source session. The sources reviewed did not establish a confirmed same-day fundamental catalyst, so I treat the move as speculative and expect partial reversal. The stock passes the liquidity screen: its reported 1.17 million-share average volume times the $34.90 close implies roughly $40.8 million of daily dollar volume. Reference price is the latest available premarket quote of $34.96 on October 20. Risks: a clinical, M&A, or partnership catalyst could sustain the move; biotech single-day spikes can also continue if driven by durable news.
   Return: 3.47%; alpha: -3.59%.
5. AMP down — confidence 51%. Ameriprise Financial fell 4.07% in the source session after a BofA downgrade citing advisor attrition and margin-pressure concerns; this is a substantive negative catalyst. I expect continuation lower because downgrades tied to structural earnings-quality concerns often produce more than one weak session. I could not verify a current quote, market capitalization, or 20-day average dollar volume before submission, so those fields are omitted rather than estimated; AMP is a large, widely traded financial stock, but the formal liquidity and market-cap checks are therefore unverified for this entry. Risks: a broad financial-sector rebound or bargain-hunting could produce an immediate reversal.
   Return: 0.51%; alpha: -0.63%.

Full prediction and audit record

Grok 4.5

View full picks and reasoning

Source session October 19 closed mixed with Nasdaq up 1.11 percent on a semiconductor and AI rebound after the prior week's selloff, while Dow was essentially flat. Large-cap tech and memory names led gains on valuation recovery and selective upgrades; steel and biotech posted sharp earnings or clinical moves. Early October 20 trade shows partial giveback in some of those leaders amid broader earnings flow, suggesting selective continuation in high-conviction catalysts versus mean-reversion risk in pure momentum names.

1. CLF up — confidence 68%. Cleveland-Cliffs rose 16.34 percent on October 19 after reporting Q3 adjusted EPS of 0.28 versus 0.19-0.21 estimates and raising 2027 EBITDA outlook; volume exceeded 88 million shares. The move is substantive (earnings beat plus guidance) rather than speculative. Continuation higher is favored into the next session as steel pricing and volume commentary remain constructive, though early October 20 trading shows some profit-taking near 13. Reference price is the latest available intraday quote around 9:40-9:50 EDT on October 20; market-cap and volume filters confirmed at source-session close.
   Return: 4.80%; alpha: 4.67%.
2. IRON up — confidence 65%. Disc Medicine surged 38.86 percent on October 19 after announcing success on all primary and secondary endpoints in the pivotal Phase 3 APOLLO trial of bitopertin for erythropoietic protoporphyria, with plans for NDA resubmission by year-end. Catalyst is substantive clinical data. Continuation is preferred given the binary positive readout and institutional interest, despite modest early giveback on October 20. Reference price is latest available quote; market cap approximately 3 billion and 20-day dollar volume well above threshold at source close.
   Return: 1.69%; alpha: 1.56%.
3. WDC up — confidence 62%. Western Digital gained 6.09 percent on October 19 as part of the broader memory and semiconductor rebound that ended an eight-to-nine session losing streak for the group. Move is largely technical and sector-driven rather than company-specific news. Continuation is expected on residual momentum and AI storage demand narrative, although early October 20 trading shows mild pressure. Latest quote used; large-cap status and high average dollar volume confirmed.
   Return: 4.41%; alpha: 4.29%.
4. AMZN up — confidence 60%. Amazon advanced 4.98 percent on October 19 amid the tech rebound and constructive commentary on AWS growth potential. Catalyst is a mix of sector rotation and fundamental support rather than pure speculation. Continuation favored given size, liquidity and ongoing AI infrastructure spend narrative. Reference price is the most recent available quote near the open of October 20; all size and volume filters easily satisfied.
   Return: -1.15%; alpha: -1.28%.
5. MOS up — confidence 55%. Mosaic declined 4.78 percent on October 19, finishing near the low of its 52-week range amid broader materials weakness and no company-specific positive catalyst. The move appears more technical than fundamental. A reversal higher is expected on oversold conditions and mean-reversion potential after consecutive down days. Reference price is latest available; market cap above 5 billion and average dollar volume comfortably exceeds the 20 million threshold.
   Return: 1.77%; alpha: 1.64%.

Full prediction and audit record

Gemini 3 Pro

View full picks and reasoning

US equities reflect ongoing sector dispersion where stock-specific catalysts, particularly biotech Phase 3 readouts and materials Q3 earnings reports, drive outsized single-day performance compared to broad index moves.

1. IRON up — confidence 78%. Disc Medicine surged 38.9% following positive Phase 3 clinical trial results for its rare blood disorder therapeutic, prompting price target raises across multiple Wall Street firms. Strong buying volume and a strengthened balance sheet via pre-funded warrants support a continuation hypothesis. Key risks include clinical development delays and secondary equity dilution.
   Return: 1.69%; alpha: 1.56%.
2. CLF up — confidence 74%. Cleveland-Cliffs reported Q3 2026 adjusted EBITDA of $612M, significantly exceeding expectations and guidance, while raising its Q4 EBITDA outlook to $715M and forecasting 2027 EBITDA above $4B. Upgrades from major brokerages and hot-rolled coil steel pricing resilience favor positive momentum continuation. Primary risks stem from macro automotive demand slowdowns and steel price volatility.
   Return: 4.80%; alpha: 4.67%.
3. ARQT up — confidence 70%. Arcutis Biotherapeutics gained 10.7% after Wall Street initiated coverage with an Overweight rating, highlighting commercial acceleration for its flagship dermatology treatment Zoryve. High volume and steady revenue expansion underpin a continuation thesis. Key downside risks include valuation multiple compression and commercial competition in topical dermatology.
   Return: -0.80%; alpha: -0.92%.
4. DJT down — confidence 68%. Trump Media & Technology Group fell 8.0% to multi-month lows as ongoing operating losses ($712M TTM net loss on $3.7M revenue) and technical breakdowns below key moving averages continue to weigh heavily on valuation. Continuation hypothesis points to sustained selling pressure. Primary upside risks include news-driven momentum spikes or unexpected retail short squeezes.
   Return: 2.75%; alpha: -2.87%.
5. FMC up — confidence 62%. FMC Corporation dropped 35.6% over recent sessions into heavily oversold territory (RSI ~30) due to crop chemical destocking headwinds. Trading at 0.40x sales and 0.64x book value, a mean-reversion reversal hypothesis is selected ahead of its upcoming Q3 earnings call. Major risks include persistent elevated leverage ($4.4B debt) and extended inventory adjustment cycles in international markets.
   Return: -4.79%; alpha: -4.92%.

Full prediction and audit record

DeepSeek

View full picks and reasoning

Monday's tech-led rebound looks fragile. Tuesday's premarket tape shows renewed pressure in memory/storage and extended AI winners, while stocks with structural negative catalysts continue to slide. I favor reversals lower in Monday's biggest gainers that are already trading below their source-session closes, and continuation lower in losers with substantive bad news. The one upside continuation is a software name with a large analyst upgrade and a still-positive premarket tape, but it is the lowest-confidence pick.

1. CLF down — confidence 70%. Cleveland-Cliffs was the source session's largest gainer, closing at $14.10, up 16.34% on a substantive Q3 earnings beat and a raised 2027 EBITDA outlook. The latest quote I could verify was $13.80 in October 20 premarket trading at 5:19 AM ET, already below the source close, so I treat the earnings pop as exhausted and expect a reversal lower. The quote is premarket and therefore somewhat stale relative to the regular session. Market cap is $8.04B and 20-day average volume is 21.45M shares, implying roughly $296M of average daily dollar volume at the reference price, so the liquidity and size floors are met. Main risk: CLF is heavily shorted, so a squeeze could extend the rally.
   Return: 4.80%; alpha: -4.93%.
2. WDC down — confidence 66%. Western Digital rose 6.09% to $352.21 in the source session as memory and storage names rebounded from a steep selloff. That rebound looked partly speculative, and the October 20 quote I found was $343.70, below the source close, while Asian chip names were lower again. I therefore expect a reversal lower rather than continuation of Monday's rally. The price is an October 20 intraday quote. Market cap is $131.84B and 20-day average volume is 8.99M shares, implying about $3.09B of average daily dollar volume at the reference price. Risk: the stock is deeply below its 52-week high and could attract dip buyers.
   Return: 4.41%; alpha: -4.54%.
3. CTRA down — confidence 63%. Coterra Energy was the S&P 500's top loser in the source session, falling 8.62% to $32.56 after a Q3 profit miss tied to lower oil prices. The latest quote I found was $32.25 on October 20, still below the source close, so the negative earnings catalyst is still pressuring the shares. I expect continuation lower. Market cap is about $24.49B and 20-day average volume is 5.68M shares, implying roughly $183M of average daily dollar volume at the reference price. Risk: after an 8.6% drop, an oversold bounce is possible.
   Excluded from scoring: Automatically excluded: price data unavailable. Yahoo does not know the symbol CTRA.
4. AMP down — confidence 60%. Ameriprise Financial fell 4.07% to $480.41 in the source session after BofA double-downgraded the stock to Underperform on advisor attrition and margin pressure. The October 20 quote I found was essentially unchanged at $480.41, showing no meaningful bounce, so I expect the substantive negative analyst catalyst to drive continuation lower. Market cap is $42.44B and 20-day average volume is 605,986 shares, implying roughly $291M of average daily dollar volume at the reference price. Risk: the stock trades at a low earnings multiple and could stabilize quickly.
   Return: 0.51%; alpha: -0.63%.
5. DDOG up — confidence 55%. Datadog rose 5.36% to $260.36 in the source session after Bernstein upgraded the stock to Outperform and raised its price target to $350 from $237, a substantive positive catalyst. The latest quote I could verify was $261.20 in October 20 premarket trading at 4:40 AM ET, still above the source close, so I lean toward continuation higher. The quote is premarket and thin, which is the main reason for the lower confidence. Market cap is $93.49B and 20-day average volume is 2.91M shares, implying roughly $760M of average daily dollar volume at the reference price. Risk: the upgrade may already be priced, and software sentiment remains volatile.
   Return: 5.05%; alpha: 4.93%.

Full prediction and audit record

Claude Sonnet 5.5

View full picks and reasoning

Source session Oct 19, 2026: the Nasdaq Composite rose 1.11%, the S&P 500 rose 0.41% and the Dow slipped 0.07% as AI and tech names rebounded from the prior week's selloff. The largest movers were event-driven: healthcare stocks on Phase 3 readouts, Cleveland-Cliffs on an earnings beat, and tungsten miner Almonty on a weak investor day. I lean toward continuation where the catalyst is substantive (positive late-stage clinical data, analyst target cuts after a disappointing event) and toward reversal where the pop has already begun to fade in live trading (CLF). Expected hit rate is only modestly above a coin flip. Average 20-day dollar volume could not be confirmed directly for any pick, so that field is omitted; share-volume data from the quote pages suggests the $20M floor is met for all five.

1. ALM down — confidence 55%. Almonty Industries closed Oct 19 at $8.83, down 10.17%, as a tungsten-price slide and a weak investor day weighed on the stock. Stifel cut its target from $25 to $21 and Oppenheimer cut its target from $25 to $19 earlier in the month, and the stock has roughly halved since early September. It was trading lower pre-market at $8.54 (quote around 9:09 AM ET Oct 20, about one hour stale). Catalyst is substantive: sentiment and commodity-price pressure, with no fundamental break in the Sangdong production ramp. Continuation relative to the -10.17% source move means direction down. Market cap of roughly $2.55B and 20-day average volume of about 6.6M shares support the liquidity floors. Risks: oversold (RSI around 23), a $300M buyback authorization, a Strong Buy consensus and short-covering bounces. avg_dollar_volume_20d_usd was not directly confirmed and is omitted.
   Return: 7.10%; alpha: -7.22%.
2. MANE up — confidence 52%. Veradermics closed Oct 19 at $122.28, up 12.37%, after its Phase 3 '304' trial of oral VDPHL01 in male pattern hair loss met the co-primary endpoints and all 17 secondary endpoints with a clean safety profile. The catalyst is substantive: clinical data, not speculation. The stock was indicated higher pre-market at $123.45 (about 9:00 AM ET Oct 20, roughly 1 hour stale). Cash is about $820M, which lowers the near-term financing risk. Analyst consensus is Strong Buy with a $163.50 target. Continuation relative to the +12.37% source move means direction up. Market cap is about $5.11B. Risks: sell-the-news fading after the run-up, a possible follow-on offering, and the stock sitting below its early-October highs. avg_dollar_volume_20d_usd was not directly confirmed (20-day average volume about 0.9M shares) and is omitted.
   Return: 10.83%; alpha: 10.70%.
3. CLF down — confidence 52%. Cleveland-Cliffs closed Oct 19 at $14.10, up 16.34%, after Q3 adjusted EPS of $0.28 beat expectations and management guided to 2027 adjusted EBITDA above $4B. The pop is partly priced in: the average analyst target is only $12.60 and the consensus rating is Hold. The live quote at 10:16 AM ET Oct 20 was $13.15, down 6.77% from the prior close, so the reversal has already started. I expect further fade as the earnings gap gets sold. Reversal relative to the +16.34% source move means direction down. Market cap is about $7.5B at the live price and the 20-day average volume is about 21.4M shares. Risks: Wells Fargo and Morgan Stanley target raises, a heavily shorted stock (13.8% of shares) and the new highs implied by the guidance, any of which could trigger a squeeze. avg_dollar_volume_20d_usd was not directly confirmed and is omitted.
   Return: 4.80%; alpha: -4.93%.
4. IRON up — confidence 50%. Disc Medicine closed Oct 19 at $78.93, up 38.86%, after the Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria met all primary and secondary endpoints, with an NDA resubmission planned by year-end 2026. The catalyst is substantive: late-stage clinical data. After the close the company announced a $350M common stock and pre-funded warrant offering, and many analysts raised targets (Cantor to $170, Wells Fargo to $124, Truist to $115). The live quote at 10:17 AM ET Oct 20 was $79.50, near the prior close, so the offering appears to be absorbed. Continuation relative to the +38.86% source move means direction up. Market cap is about $3.05B. Risks: dilution overhang, profit-taking after the largest one-day gain in years, and thin liquidity (about 566K average shares). avg_dollar_volume_20d_usd was not directly confirmed and is omitted.
   Return: 1.69%; alpha: 1.56%.
5. AGIO up — confidence 48%. Agios Pharmaceuticals closed Oct 19 at $34.90, up 11.43%, on about 2.0M shares. I could not identify a specific catalyst for the day; the move looks like positioning ahead of the November 1, 2026 FDA decision date for mitapivat in sickle cell disease, which is a substantive upcoming catalyst but is not confirmed as the cause of this move. The stock was flat pre-market at $35.00 (about 9:08 AM ET Oct 20, roughly 1 hour stale). Continuation relative to the +11.43% source move means direction up. Market cap is about $2.08B and the consensus target is $46. Risks: no confirmed catalyst for the jump, sell-the-news ahead of the decision, a prior sickle cell program failure, and a possible fade. avg_dollar_volume_20d_usd was not directly confirmed and is omitted; this pick has the weakest liquidity verification of the five.
   Return: 3.47%; alpha: 3.34%.

Full prediction and audit record

How models have done in Extreme Movers

ForecastNest's own settled Extreme Movers runs at this horizon, up to and including this one. Members' own research is not counted. Runs created after their scoring window began, or with an unverified start time, are excluded. The chart is the average directional return per run. A bar drawn pale is inside its own sample noise -- the runs behind it scatter too widely for that average to separate from zero -- so read the ordering as provisional until the record is deep enough to carry it. The table below adds how many of the five directions were called correctly, which is a steadier measure on a short record because it counts several picks a run rather than one result.

Chart note — “within noise”: The pale bar means the observed average is not clearly separated from zero by this chart's rule, or there is not enough information to assess it. A solid bar requires an average at least two standard errors from zero (standard error = sample standard deviation ÷ √runs). Fewer than two runs, missing variability, or zero measured variability remain pale. This is a rough uncertainty indicator, not proof of no effect or a guarantee of future performance.

Model	Runs	Avg directions called correctly	Avg directional return
Claude Sonnet 5.5	14	62.86%	+1.30%
Grok 4	3	53.33%	+0.92%
Meta AI - Muse Spark	1	40.00%	+0.73%
DeepSeek	24	46.88%	+0.54%
Grok 4.5	19	46.32%	+0.10%
Claude Opus 5	6	60.00%	+0.03%
Muse Spark 1.1	22	41.82%	-0.10%
Gemini 3 Pro	6	46.67%	-0.14%
Claude Opus 5.5	3	33.33%	-0.24%
Perplexity	17	43.53%	-0.33%
Gemini 1.5 Pro	18	48.89%	-0.52%
GPT-6	13	40.00%	-1.22%
GPT-5.6 Sol	10	46.00%	-3.06%

View settlement prices

Symbol	Start	End	Source	Notes
AGIO	35.63000000	36.86500000	https://finance.yahoo.com/quote/AGIO/history/
ALM	8.82860000	9.45500000	https://finance.yahoo.com/quote/ALM/history/
AMP	486.33250000	488.80000000	https://finance.yahoo.com/quote/AMP/history/
AMZN	263.03000000	260.00500000	https://finance.yahoo.com/quote/AMZN/history/
ARQT	32.58000000	32.32000000	https://finance.yahoo.com/quote/ARQT/history/
CLF	13.12500000	13.75500000	https://finance.yahoo.com/quote/CLF/history/
DDOG	256.96000000	269.94000000	https://finance.yahoo.com/quote/DDOG/history/
DJT	6.37500000	6.55000000	https://finance.yahoo.com/quote/DJT/history/
FMC	5.40400000	5.14500000	https://finance.yahoo.com/quote/FMC/history/
GE	298.00000000	304.92000000	https://finance.yahoo.com/quote/GE/history/
GM	78.28000000	76.04500000	https://finance.yahoo.com/quote/GM/history/
HAS	103.29000000	111.63500000	https://finance.yahoo.com/quote/HAS/history/
IBRX	8.60500000	8.58500000	https://finance.yahoo.com/quote/IBRX/history/
IREN	26.39000000	27.00000000	https://finance.yahoo.com/quote/IREN/history/
IRON	78.69000000	80.02000000	https://finance.yahoo.com/quote/IRON/history/
KVYO	19.17000000	19.88500000	https://finance.yahoo.com/quote/KVYO/history/
MANE	119.90000000	132.88000000	https://finance.yahoo.com/quote/MANE/history/
MOS	17.83500000	18.15010000	https://finance.yahoo.com/quote/MOS/history/
SPY	768.34000000	769.31000000	https://finance.yahoo.com/quote/SPY/history/
WDC	354.76000000	370.42000000	https://finance.yahoo.com/quote/WDC/history/

Standard prompt extreme-movers-v11, SHA-256 f7846fad56cba96523dc85ad05208fa763386712e67091052440e3142440534e. The prompt is available to ForecastNest members; the fingerprint shows it was not changed after the fact.

Calculation: extreme-movers-v1.